Immunome Q1 EPS $(2.51) Misses $(0.69) Estimate, Sales $1.03M Miss $2.50M Estimate
Portfolio Pulse from Benzinga Newsdesk
Immunome reported a significant miss in Q1 earnings and sales, with EPS at $(2.51) versus the $(0.69) estimate and sales at $1.03M against the $2.50M estimate. This represents a substantial decrease from the previous year's figures.
May 14, 2024 | 12:18 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Immunome's Q1 earnings significantly missed estimates with a larger loss per share and lower sales than expected, indicating potential short-term negative impact on stock price.
The substantial miss in both earnings per share and sales compared to analyst estimates, along with a significant decrease from the previous year's figures, could lead to negative investor sentiment and a potential decrease in stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100